Traditions of Quality on The Russian Market

Servier is an international pharmaceutical company that has been operating in Russia for almost 30 years, and is one of the top ten largest pharmaceutical companies in the country. Servier actively invests in the Russian economy and was one of the first European companies to bring their innovative pharmaceutical production technology to Russia, having done so in 2005.
SERVIER RUS is a high tech production facility in Moscow that employs over 200 highly-skilled specialists, and operates in full compliance with the Good Manufacturing Practices (GMP). Today, over 90% of Servier's original medicines are produced at this plant.

Servier mostly produces medicines for the treatment of common, chronic, non-communicable diseases, such as cardiovascular diseases, diabetes mellitus, and chronic venous insufficiency. Demand for these medicines is growing continuously in Russia. In the 2018/2019 fiscal year alone, the facility's output increased by 13.4%, producing 40.9 million packages.
Jérôme Gavet
Managing Director, Servier, Russia & Eurasian Economic Union
"We appreciate the comprehensive assistance and support of the Moscow Government, thanks to which we are successfully developing original medicines for the treatment of common, chronic, non-communicable diseases in Russia, and are increasing output to provide Russian patients with these medicines as well as to export them to EAEU member states. We are planning to expand these exports to countries in Central Asia and in the European Union."
The plant has been actively implementing a Russian Government strategy aimed at supporting and developing export-oriented enterprises. In 2017, SERVIER RUS began exporting medicines to the member states of the Eurasian Economic Union (EAEU). There are plans to expand these exports to include countries in Central Asia and the European Union.

In 2016, the Moscow Government awarded SERVIER RUS the status of industrial complex. The tax exemptions granted as a result of this have saved company funds that can be reinvested into further developing and modernising the plant.

For instance, in April 2019, the plant launched a new line for the contract manufacturing of a ground-breaking HIV medicine in partnership with GSK/ViiV Healthcare, another top pharmaceutical company.
Integrated production line
Another example is the full systemic modernization of the plant's laboratories, which was comple­ted in 2019, allowing for medicine quali­ty control to be optimized at all stages of production. These investments to modernize the labo­ratory and renovate the office premises have exceeded €2 million.

One of the most prominent investments of the past few years was the government's medicine labelling project. Servier was one of the first companies to join the project in 2017, having invested a total of €3 million into it since then. Thanks to the concerted efforts of a cross-functional team made up of Russian and French specialists, the company announced in December 2019 that they were ahead of schedule and have launched a medicine labelling and tracing system at SERVIER RUS.
The first labelled medicine batches for commercial use were produced in December 2019
Thanks to the use of advanced production technologies and extremely strict quality control across all production stages, the medicines manufactured at Servier's Moscow plant are identical in qua­lity to those manufactured at other Servier plants across the world.
Audience: 16+